Edgewise Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Author's Avatar
May 11, 2023

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, today reported financial results for the first quarter of 2023 and recent business highlights.